Carfilzomib produces OS benefit vs. bortezomib in relapsed, refractory disease March 30, 2017Vol.40 No.03
Conversation with The Cancer Letter Fran Visco: We should be partners on every level, not just when the NIH budget is threatened March 24, 2017Vol.43 No.12By Paul Goldberg
Conversation with The Cancer Letter Rick Klausner: This is a profoundly disturbing statement about dramatically de-prioritizing research, science, and biomedical research March 24, 2017Vol.43 No.12By Paul Goldberg
Free “Duplicity” at NIH? White House spokesman Sean Spicer says the cut isn’t really a cut March 17, 2017Vol.43 No.11
Conversation with The Cancer LetterFree Patricia Goldsmith: This is the “Moonstab,” or, maybe, the “Moonshaft” March 17, 2017Vol.43 No.11By Matthew Bin Han Ong
Conversation with The Cancer LetterFree Blase Polite: This was put together by folks who have no sense of how research is done March 17, 2017Vol.43 No.11By Matthew Bin Han Ong
Conversation with The Cancer LetterFree Ellen Sigal: This is not a grasstops issue anymore, this is really grassroots March 17, 2017Vol.43 No.11By Matthew Bin Han Ong
